Oncolytic viral replication (OV replication)

Oncolytic viral replication refers to the specialized process by which naturally occurring or genetically engineered viruses selectively infect, replicate within, and destroy cancer cells while sparing normal tissue. This selectivity often exploits inherent defects in tumor cells, such as impaired interferon (IFN) signaling pathways or overactive Ras signaling, which prevent the host cell from mounting an effective antiviral response (Source: NIH, PubMed). As the virus replicates, it culminates in oncolysis—the physical rupture of the cancer cell—which releases viral progeny to infect adjacent tumor cells and disperses tumor-associated antigens into the microenvironment. Beyond direct cytotoxicity, oncolytic viral replication serves as a potent catalyst for the immune system by inducing immunogenic cell death (ICD). This process transforms the often 'cold' immunosuppressive tumor microenvironment into a 'hot' environment, attracting and activating dendritic cells and T-cells through the release of damage-associated molecular patterns (DAMPs) and cytokines (Source: Nature Reviews Cancer). Modern therapeutic approaches involve engineering viruses to carry therapeutic transgenes, such as GM-CSF, to further enhance the systemic anti-tumor immune response. While highly promising, challenges remain regarding the delivery of the virus to metastatic sites and the rapid clearance of the virus by the host's pre-existing or treatment-induced neutralizing antibodies.

Other names

Oncolytic virotherapyViral oncolysisSelective viral replicationOncolytic virus therapyVirotherapy

Selective infection and replication within cancer cells followed by cell lysis and induction of systemic anti-tumor immunity.